News

Biofuels producers join forces
Enlarge image

PolicyBelgiumEUGermanyItalyUKFinland

Biofuels producers join forces

11.02.2013 - Seven leading producers of second generation biofuels have joined forces in an industry initiative to support uptake of their technology.

The initiative, named “Leaders of Sustainable Biofuels”, aims at supporting the development of second generation biofuels as a sustainable alternative to fossil fuels in Europe. The leaders of Chemtex, British Airways, BTG, Chemrec, Clariant, Dong Energy and UPM are joining forces to ensure the market uptake of advanced sustainable biofuels by all transport sectors. The Chief Executive Officers of the companies suggested biofuels were cost-competitive and had less environmental impact than fuels made from oil or natural gas. They argue that second-generation biofuels can reduce GHG emissions by at least 65%.

In contrast, first generation biofuels, made from corn, wheat, soy or palm provide only modest reductions in greenhouse gases and can push up food prices. At the initiative’s launch in Brussels, the “Leaders of Sustainable Biofuels” demanded to accelerate research and innovation into emerging biofuel technologies, including algae and new conversion pathways, supported by public and private R&D programmes. They said it were important to develop worldwide accepted sustainability certification and to establish financing structures to facilitate the implementation of sustainable biofuel projects. The initiative aims at promoting the benefits of advanced sustainable biofuels and to address national policy makers, the European Commission and the European Parliament. The “Leaders are convinced that their biofuels are key for the reduction of fossil energy imports in the EU”. 

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/biofuels-producers-join-forces.html

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF47.6%
  • CYTOS0.32 CHF45.5%
  • FORMYCON13.90 EUR39.1%

FLOP

  • ACTELION100.70 CHF-15.1%
  • MOLOGEN5.72 EUR-13.7%
  • BIOFRONTERA2.02 EUR-12.2%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR96.5%
  • FORMYCON13.90 EUR80.5%

FLOP

  • CYTOS0.32 CHF-90.3%
  • 4SC0.82 EUR-50.9%
  • MOLOGEN5.72 EUR-50.8%

No liability assumed, Date: 27.01.2015